AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Human Resistin for the Treatment of Sepsis

Technology Application

Use of human resistin to treat sepsis.Use of human resistin to modulate inflammation in TLR-4 mediated diseases.

Detailed Technology Description

None

Others

Background

An estimated 750,000 people in the US are diagnosed with sepsis and the annual costs for treating sepsis in hospitals was $23 billion in 2013. Sepsis is not directly caused by an infection but by the body’s overwhelming immune response to the infection. The subsequent immune response often destroys tissue, causes organ failure and may result in death. The incidence in sepsis is rising, and the mortality rate remains high, reaching 30-40% in patients with severe sepsis and 50-60% in those who develop septic shock.

Currently there are no effective treatments that directly target the aggressive immune response that causes sepsis. Given that there is no direct treatment, the standard of care for sepsis at this time is limited to antibiotics and supportive care. Thus new and effective therapies for sepsis are desirable.

Related Materials

Jang, J. et al. Human resistin protects against endotoxic shock by blocking LS-TLR4 interaction. Proc Natl Acad Sci USA November 8, 2017

Tech ID/UC Case

29029/2016-672-0

Related Cases

2016-672-0

Country/Region

USA

For more information, please click Here